drugset / Trial / NCT04812431
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
Phase 1/2
Recruiting
5 enrolled
S.Biomedics Co., Ltd.
Linical Co., Ltd. · collabYonsei University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.
Timeline
- Start
- 2021-09-23
- Primary completion
- 2028-10
- Completion
- 2030-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PSA-NCAM(+) NPC | Cell therapy | — | Intrathecal |